Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025
December 24, 2025 — Zai Lab Limited (NASDAQ: ZLAB, HKEX: 9688) is back in the spotlight after a major regulatory catalyst in China helped lift sentiment around the biopharma name. The company announced that China’s National Medical Products Administration (NMPA) approved COBENFY (xanomeline and trospium chloride) for schizophrenia in adults—a decision that quickly rippled into trading on both its U.S. ADR and Hong Kong listings. Business Wire+1 As of Dec. 24, 2025, Zai Lab’s U.S.-listed ADR was trading around $18.54 intraday (open $18.39, high $19.01), as risk-on buyers reacted to the approval headline and the company’s broader “pipeline-to-commercial” story. MarketBeat